Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test.

British Journal of Clinical Pharmacology

Volumn 38, Issue 5, 1994, Pages 471-473

  Bertilsson, L ^a   Carrillo, JA ^a   Dahl, ML ^a   Llerena, A ^a   Alm, C ^a   Bondesson, U ^a   Lindstrom, L ^a   Rodriguez de la Rubia, I ^a   Ramos, S ^a   Benitez, J ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CLOZAPINE; CYTOCHROME P450 ISOENZYME; DEBRISOQUINE; MEPHENYTOIN;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DEMETHYLATION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VOLUNTEER;

ADMINISTRATION, ORAL; ARYLAMINE N-ACETYLTRANSFERASE; CAFFEINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLOZAPINE; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; METHYLATION; OXIDOREDUCTASES; SWEDEN; XANTHINE OXIDASE;

EID: 0027985726     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1994.tb04385.x     Document Type: Article

References (18)

1. Clozapine. A novel antipsychotic agent
2. Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings
3. Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans
4. Plasma levels of thioridazine and metabolites are influenced by the debrisoquine hydroxylation phenotype
5. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype
6. Genetically variable metabolism of antidepressants and neuroleptic drugs in man
7. Disposition of clozapine in man: Lack of association with debrisoquine and S‐mephenytoin hydroxylation polymorphisms
8. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service
9. Fluvoxamintricyclic antidepressant interaction: an accidental finding
10. Interaction between fluvoxamine and imipramine/desipramine in four patients
11. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects
12. The debrisoquine hydroxylation test predicts steady‐state plasma levels of desipramine
13. Fluvoxamine is a potent inhibitor of cytochrome P4501A2
14. The use of caffeine for enzyme assays: A critical appraisal
15. Caffeine metabolism in a healthy Spanish population: N‐acetylator phenotype and oxidation pathways
16. Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA‐expressed human CYP1A2 and CYP2E1
17. Dose‐related plasma levels of clozapine: influence of smoking behaviour, sex and age
18. Effect of phenytoin, carbamazepine, and valproic acid on caffeine metabolism